OLYSIO
PeakNDAORALCAPSULEPriority Review
Approved
Nov 2013
Lifecycle
Peak
Competitive Pressure
8/100
Data completeness
2/8 — Basic
Priority Review
Drug data last refreshed 8h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
OLYSIO is an oral small-molecule capsule approved by FDA in November 2013 for a hepatitis C indication. The drug represents Johnson & Johnson's entry into the direct-acting antiviral (DAA) space, though specific mechanism and indication details are not provided in available data.
Peak3.1 years to LOE
Product is at peak commercial stage with high competitive pressure (8/10), indicating active brand team with defensive positioning strategy required as market matures.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
LOE in ~4 years — strategic planning for patent cliff underway
Worked on OLYSIO at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.